Acebutolol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acebutolol

Property Description
Active Ingredient Acebutolol hydrochloride
Form Oral tablets or capsules
Pharmacological Class Beta-adrenergic receptor blocker (beta-blocker)
Key Characteristics Cardioselective, possesses Intrinsic Sympathomimetic Activity (ISA)
Origin Synthetic compound

Acebutolol is a synthetic, single-ingredient cardiovascular medicine belonging to the pharmacological class of Beta-adrenergic receptor blockers, commonly known as beta-blockers. Its primary function is to help manage conditions related to elevated blood pressure and irregular heart activity by modulating the impact of stress hormones on the heart. The active substance is Acebutolol hydrochloride, an agent designated for prescription-only use in solid oral forms. Pharmacological studies have clinically recognized Acebutolol for its role in promoting stable heart function.


What Type of Medicine is Acebutolol?

Acebutolol is specifically classified as a second-generation beta-blocker that is cardioselective, meaning it preferentially targets the beta-1 receptors found mainly in the heart. This selectivity is a defining characteristic that differentiates it from non-selective beta-blockers, contributing to its particular pharmacological profile. As a beta-blocker, the medication works by blocking the excessive effects of adrenaline and related hormones, thereby moderating the heart's rate and reducing the force of its contractions. Acebutolol and its metabolite, Diacetolol, exhibit both beta-adrenergic blocking activity and membrane stabilizing activity. This indicates the medicine has a dual role in controlling heart rate and stabilizing the electrical activity of the heart muscle.


Acebutolol's Unique Profile: Cardioselectivity and ISA

Acebutolol is uniquely distinguished by its cardioselectivity and the presence of Intrinsic Sympathomimetic Activity (ISA), a mechanism that provides a balanced action of receptor blockade and mild, internal stimulation. This means that while the drug blocks the powerful effects of external adrenaline, it acts as a partial agonist to provide a mild, baseline level of stimulation. The presence of ISA sets it apart from many other beta-blockers that are pure antagonists, a feature often investigated in research for its potential to mitigate common beta-blocker effects. Acebutolol is an established agent for conditions requiring heart function control.


What are the Composition and Forms of Acebutolol?

The medication is a single-component, synthetic compound formulated into oral dosage forms, most commonly as Tablets or Capsules for ease of administration. The core composition involves the active ingredient Acebutolol hydrochloride combined with pharmaceutical excipients necessary for stability and structure. While Acebutolol is the International Nonproprietary Name (INN), it is widely known under the brand name Sectral in some markets. This preparation ensures that Acebutolol is conveniently delivered via the oral administration route for long-term daily management of cardiovascular disorders.

Regulatory References

  1. U.S. National Library of Medicine

What side effects are possible with Acebutolol?

Possible Side Effects and Safety Information

The safety profile of Acebutolol is defined by adverse reactions classified according to their frequency and the physiological systems affected, as documented in government regulatory sources (e.g., FDA and SmPC labeling).


Officially Documented Adverse Reactions

The officially listed side effects are typically grouped by incidence rate:

  • Common Reactions (affecting ge 1% of patients): These often involve the central nervous system, such as dizziness, headache, and fatigue. Gastrointestinal effects like nausea, dyspepsia, and abdominal pain are also commonly reported, along with hypotension (low blood pressure) and bradycardia (slow heart rate).

  • Uncommon Reactions: These include sleep disturbances (insomnia), anxiety, and depression.

  • Rare Reactions: Less frequent but documented effects include hepatic toxicity (liver enzyme elevations), vision disturbances, paresthesia (tingling), and specific cardiovascular events such as heart block.


Serious Safety Considerations

Regulatory documents highlight several serious safety considerations and explicit limitations for use:

  • Contraindications: Acebutolol must not be used in individuals with conditions such as severe sinus bradycardia, second- or third-degree heart block, overt cardiac failure, or cardiogenic shock.

  • Abrupt Withdrawal Risk: Suddenly stopping the medicine may lead to a worsening of heart conditions, including the exacerbation of angina pectoris or myocardial infarction, a pattern that necessitates gradual cessation under medical guidance.

  • Population Specificity: Caution is advised for patients with renal impairment due to the risk of drug accumulation, and for those with hepatic impairment given the documented risk of liver abnormalities.

Overdose and Emergency Response

Acebutolol Overdose and when to seek help

Suspected overdose of Acebutolol requires immediate medical attention due to the potential for severe cardiovascular and neurological complications. The official regulatory guidance mandates contacting emergency services immediately upon recognizing any signs of overdosage.

Documented manifestations of Acebutolol overdose primarily affect the heart and circulation. These include severe bradycardia (slow heart rate), profound hypotension (low blood pressure), severe congestive heart failure, and the development of advanced atrioventricular (AV) block. Owing to the drug's properties, overdose may also lead to intraventricular conduction defects and QTc prolongation.

Systemic effects include seizures, mental confusion, and a progressive state of drowsiness potentially leading to coma. A critical metabolic finding is hypoglycemia (low blood sugar), which is noted as particularly significant in children.

Treatment for overdose is defined as symptomatic and supportive, as no specific antidote is known. Measures described in regulatory guidance include gastrointestinal decontamination, such as the administration of activated charcoal. Hospital monitoring is required, often involving continuous cardiac monitoring and serial laboratory checks to manage the potential for life-threatening outcomes like cardiogenic shock or cardiac arrest.

Therapeutic Uses of Acebutolol

Acebutolol is a prescription medication commonly used across conditions presenting with acute episodes where supportive symptom management is appropriate. Its main therapeutic domain is in cardiovascular care. Its primary indications are the management of hypertension (high blood pressure) and certain types of ventricular arrhythmia, specifically ventricular premature beats.

This medication may assist with aspects of symptoms related to heightened physiological activity. This helps with the management of blood pressure and supports the patient by contributing to easing the overall symptom load associated with these conditions. For individuals experiencing heart rhythm disturbances, acebutolol may assist with maintaining a sense of stability when functional stability becomes affected by irregularities. This provides supportive relief for managing symptoms that interfere with daily functioning due to high blood pressure or heart rhythm irregularities.

The therapeutic use of this medication is focused on the management of hypertension and the management of ventricular premature beats.

Quick Fact: Supports symptoms related to systemic imbalance

Regulatory References

  1. DailyMed official labeling information

Eligibility and Restrictions for Use

Who Can and Cannot Use Acebutolol?

Eligibility for Acebutolol is strictly defined by regulatory authorities based on pre-existing medical conditions and specific population characteristics. The medicine is primarily intended for adults with established indications.

Acebutolol is contraindicated and must not be used in patients with severe, uncompensated heart conditions, including cardiogenic shock, overt (decompensated) cardiac failure, second- and third-degree heart block, and persistently severe bradycardia. Patients with a known hypersensitivity to Acebutolol or other beta-blockers are also non-eligible.

Population Group Eligibility Status (Regulatory Status)
Pediatric Population (Children) Safety and efficacy have not been established.
Lactation (Breastfeeding) Not recommended due to excretion into breast milk.
Renal Impairment Requires dosage adjustment (reduction) if Creatinine Clearance is less than 50 mL/min.
Bronchospastic Disease (e.g., Asthma) Conditional use with caution and at the lowest possible dose; generally should not receive a beta-blocker.

Use during pregnancy is conditional (FDA Category B), permitted only if the potential benefit outweighs the risk to the fetus.

What should I know about interactions with other medicines?

Acebutolol Interactions with other medicines and products

Interaction Scope

Property Description
Medicinal product categories with documented interactions: Calcium Channel Blockers, Antihypertensive Agents, NSAIDs, Alpha-Adrenergic Stimulants, Antiarrhythmics, Antacids, Anesthetics.
Mechanistic basis of interactions (only if stated in label): Pharmacodynamic Additive/Antagonistic Effects; Inhibition of Gastrointestinal Absorption; Altered Systemic Clearance.
Timing-based interaction rules (if applicable): Mandatory separation by 2 hours (with Aluminum Hydroxide); Withholding blood pressure lowering agents for 24 hours prior (with Amifostine).
Population-specific interaction notes (if applicable): Bioavailability is approximately doubled in The Elderly due to altered systemic clearance.

Interaction Classifications (High-Level)

Classification Description
Interaction severity classification (as defined in official documents): Clinically Significant Interactions (e.g., additive cardiovascular depression, antagonistic effect).
Regulatory basis (EMA / FDA / etc.): Official Prescribing Information / Summary of Product Characteristics (SmPC) from government regulatory agencies.

Resulting Interaction Structure

Official Interaction Statements:

  • Co-administration with Calcium Channel Blockers (Verapamil, Diltiazem) increases the risk of additive depression of heart rate and cardiac conduction.
  • Other Antihypertensive Agents increase the risk of hypotension due to pharmacodynamic synergism.
  • NSAIDs (e.g., Aspirin) may decrease the antihypertensive effects via pharmacodynamic antagonism.
  • Alpha-adrenergic Stimulants carry a risk of severe hypertensive reaction.
  • Aluminum Hydroxide inhibits absorption, requiring a separation of at least 2 hours between administrations.
  • Anesthetics that depress the myocardium may enhance the risk of excessive myocardial depression.

Connection to the overall interaction profile: Regulatory documents define the Acebutolol interaction structure primarily by clinically significant pharmacodynamic interactions that result in additive cardiovascular effects or antagonism of blood pressure control. The profile is further defined by pharmacokinetic interactions where substances like Aluminum Hydroxide reduce drug exposure, leading to mandatory timing separation rules that must be followed to maintain the official absorption profile.

Mechanism of Action

Selective Beta-1 Receptor Antagonism

Acebutolol is a beta1-selective adrenergic receptor blocker that functions primarily by selectively antagonizing beta1-adrenergic receptors. These receptors are predominantly expressed in the myocardial tissue (heart). This selective interaction blocks the action of endogenous catecholamines (such as norepinephrine) at this site.


Intrinsic Sympathomimetic Activity (ISA) and Pathway Effects

A key feature of acebutolol is its Intrinsic Sympathomimetic Activity (ISA), meaning it partially activates the beta1-receptor while simultaneously blocking the stronger signal from natural catecholamines. This dual action modulates the sympathomimetic stimulation and typically results in a lower degree of resting beta-blockade. Mechanistically, beta1 antagonism also includes the attenuation of renin release from the juxtaglomerular apparatus, a key step in modulating the Renin-Angiotensin-Aldosterone System (RAAS).


Resultant Physiological Effects

The blockade of beta1-receptors and the associated pathway modulation lead to a negative chronotropic (reduction in heart rate) and negative inotropic (reduction in myocardial contractility) effect. These effects reduce the workload on the heart and modulate the activity of the sinus node and specialized conduction tissue, contributing to the drug's overall systemic hemodynamic consequences.

Dosage and Administration Information

Acebutolol is exclusively administered through the oral route, typically available as 200 mg and 400 mg capsules or film-coated tablets. These solid dosage forms must be swallowed whole with water and should not be chewed or crushed. The treatment protocol involves long-term management with standardized initial dosing.

For conditions like high blood pressure, the typical starting dose is 400 mg per day, given either as a single dose or in two divided doses. For heart rhythm irregularities, the initial dosage is usually 400 mg daily divided into two doses. Maintenance dosages generally range from 400 mg to 800 mg per day, with the maximum recommended total daily dose being 1200 mg. Adjustments to the dosage should be made gradually at intervals of one week or longer.

Specific dosing rules apply to certain patient groups. For older adults, lower maintenance doses may be required, and daily dosages should not exceed 800 mg. Patients with reduced kidney function require substantial dose modification based on creatinine clearance, with up to a 75% reduction in the usual daily dose for severe impairment. If a dose is missed, it should be taken as soon as possible, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped; a double dose must not be taken. Treatment, if discontinued, must follow a procedural instruction where the dose is reduced gradually over approximately two weeks.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Acebutolol

Evidence for Use in Hypertension

Research examined Acebutolol in the context of high blood pressure, or hypertension, primarily utilizing Randomized Controlled Trials (RCTs) and comparative clinical studies. These studies were structured to examine the response in adults diagnosed with essential or mild hypertension. Research focused on monitoring changes in systolic and diastolic blood pressure readings. These trials report that the data show patterns related to changes observed in both systolic and diastolic blood pressure across various patient cohorts. Studies frequently rely on the blood pressure reading itself as the primary measure, which is a research limitation. There is limited information for long-term outcomes specifically from these trials regarding the effect on major events, such as heart attack or stroke.


Evidence for Use in Ventricular Arrhythmia

Acebutolol was evaluated in the context of certain types of irregular heartbeats, specifically ventricular arrhythmia, utilizing controlled clinical trials. These studies explored adults who were experiencing frequent ventricular ectopy. The outcomes monitored included measures describing changes in the frequency of irregular beats in the heart’s rhythm. Findings indicate patterns related to changes observed in the frequency of irregular heartbeats compared to times when a placebo was used. The evidence base for the short-term findings on arrhythmia frequency is classified as High. However, the evidence is limited because research is based predominantly on short follow-up durations.


Evidence for Secondary Prevention After Heart Attack

Research examined Acebutolol in the context of patients following a heart attack, or Post-Myocardial Infarction (MI), relying on a single major Randomized Placebo-Controlled Trial. The initial 1-year treatment phase described a pattern of differences in total mortality in the group receiving Acebutolol compared to the placebo group. Follow-up surveillance over a long-term survival survey period, extending up to five years, also reported that studies monitored how survival patterns developed in the observed populations beyond the initial treatment period. A key limitation is that the primary data on the mortality measure originates from a single, large-scale RCT.

Frequently Asked Questions (FAQ)

Common questions about Acebutolol (FAQ)

Q: How long does it typically take for Acebutolol to start lowering blood pressure?

A: Information from clinical studies indicates that the medication’s peak effect—the point where its action is strongest—generally occurs between three and eight hours after it is taken. This measurement provides a factual timeframe for when the drug is most active in the body.

Q: What happens if I miss a dose of Acebutolol?

A: Regulatory patient instructions advise that if a dose is missed, it should be taken as soon as it is remembered unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped. Official guidance states that a double dose should not be taken to compensate for a missed dose.

Q: Can Acebutolol cause changes in sleep patterns?

A: Yes, regulatory documents list sleep disturbances as a potential adverse effect associated with Acebutolol. These reported effects include experiences of insomnia (difficulty sleeping) and nightmares. This information is noted in the official prescribing information.

Q: Is it okay to exercise while taking Acebutolol?

A: Official guidance indicates that healthcare providers typically observe and monitor a patient’s exercise tolerance while on this medication. Since Acebutolol affects the heart rate, monitoring confirms that the body's response to physical activity remains within expected parameters. Information regarding physical activity should be discussed with a healthcare provider.

Q: Is there a generic version of Acebutolol available?

A: Yes, Acebutolol is manufactured and available as a generic formulation, in addition to any existing brand-name products. This information is confirmed in regulatory drug status documentation.

Q: Is Acebutolol safe for people who have asthma or other lung issues?

A: Regulatory warnings advise that caution is necessary when the medication is used by people with bronchospastic diseases, such as asthma. Official documents describe that, due to its classification, use in these patient groups may require the lowest possible dosage.

Q: How quickly does the effect of Acebutolol wear off?

A: The medication is typically designed for once-daily dosing because its effects on the body can persist for 24 hours. The duration of its primary action contributes to its utility in long-term management of cardiovascular conditions.

Q: Is Acebutolol prescribed for people who have had a heart attack?

A: Official prescribing information confirms that Acebutolol is indicated for use in managing patients following a heart attack, often referred to as post-myocardial infarction. Its use in this context has been evaluated by regulatory bodies.

Q: Is Acebutolol similar to Propranolol or Atenolol?

A: Acebutolol belongs to the same class of medicines, known as beta-blockers, as Propranolol and Atenolol. However, the official product information notes that Acebutolol is distinguished by its 'cardioselectivity' (preferentially targeting the heart) and its 'Intrinsic Sympathomimetic Activity' (a partial stimulating effect). These features define its specific pharmacological profile.

Q: Are there certain foods or drinks I should avoid while on Acebutolol?

A: Official regulatory warnings focus primarily on interactions with certain other medicines. For example, a timing separation of at least two hours is required if taking Aluminum Hydroxide antacids, which can block the drug's absorption. Broader food restrictions are not generally mandated in the main prescribing information.

Q: What should I watch out for when first starting Acebutolol?

A: When initiating therapy, patients should be alert for common effects like dizziness, headache, and fatigue. More seriously, regulatory documents advise monitoring for signs of an overly strong effect, such as excessively low blood pressure (hypotension) or a very slow heart rate (bradycardia).

Q: What if I drink alcohol while taking Acebutolol?

A: Official drug interaction warnings state that combining Acebutolol with alcohol can lead to additive effects that increase the blood pressure-lowering action. This could result in symptoms such that dizziness or lightheadedness may be increased.

Q: Can Acebutolol affect blood sugar levels?

A: Yes, according to official prescribing information, Acebutolol may cause changes in blood sugar levels. A specific caution is noted because the medication can mask some of the symptoms of low blood sugar, such as a rapid heart rate, making them harder to recognize.

Q: What is the difference between Acebutolol and other beta-1 selective blockers?

A: Acebutolol's official pharmacological profile is defined by its selective action on the beta-1 receptor, primarily found in the heart. What sets it apart is its unique feature called Intrinsic Sympathomimetic Activity (ISA), which is explicitly detailed in regulatory clinical pharmacology sections.

Q: Do studies show Acebutolol is effective for heart rhythm problems?

A: The medication is indicated for specific ventricular arrhythmias (irregular heartbeats). Research has examined its ability to change the frequency of these irregular beats, with findings indicating observed patterns related to rhythm control.

Q: Is Acebutolol safe for adolescents or children?

A: Regulatory documents explicitly state that the safety and effectiveness of Acebutolol for use in the pediatric population have not been established. This absence of data means its use in children is not established.

Q: Can Acebutolol be used if a person has kidney problems?

A: Official guidelines describe that use in individuals with reduced kidney function requires the dosage to be modified based on the degree of impairment. This adjustment is necessary because the drug is primarily processed by the body through the kidneys.

Q: Does taking Acebutolol long-term change its effectiveness?

A: Studies have been conducted to examine the sustained effects of the medication over extended periods. This research provides data on long-term patterns related to the maintenance of effectiveness in controlling heart function.

Q: Are there any known interactions between Acebutolol and common pain relievers?

A: Official interaction statements warn of an interaction with nonsteroidal anti-inflammatory drugs (NSAIDs), which includes many common pain relievers. This combination may counteract or decrease the expected blood pressure-lowering effects of Acebutolol.

Q: Does Acebutolol interact with herbal supplements?

A: Regulatory patient counseling emphasizes the importance of disclosing all other medications and supplements they are taking to a healthcare provider. This includes herbal products, as this disclosure allows for the review of potential interactions.

Q: How does Acebutolol affect cholesterol levels?

A: Clinical pharmacology observations indicate that Acebutolol has been noted to have minimal overall effects on blood lipid levels. Studies have not observed it to elevate cholesterol or related lipids during long-term therapy.

Q: Why is it important to check blood pressure regularly while on Acebutolol?

A: Regular monitoring of blood pressure is a standard requirement for this medication. This monitoring is necessary to confirm that the medication is consistently achieving and maintaining the desired systemic effect of blood pressure control.

Q: Can Acebutolol cause memory issues or confusion?

A: Official adverse reaction reports include memory loss and confusion among the less common psychological or mental effects. This information is documented in the safety profile of the medication.

How should Acebutolol be stored and disposed of?

Storage & Disposal Scope

Scope Item Official Regulatory Statement
Labeled storage temperature requirements Store at Controlled Room Temperature (CRT), 20 C to 25 C (68 F to 77 F), with permitted excursions between 15 C and 30 C (59 F to 86 F).
Light/moisture protection requirements Must be protected from light and kept away from moisture and excessive heat.
Handling requirements The product must be kept from freezing and not stored in the bathroom.
Packaging-related storage rules Dispense and store in a light-resistant, tight container and keep the container tightly closed.
Disposal instructions (as documented) Dispose of outdated or no longer needed medication. Drug take-back programs are the preferred disposal method. If unavailable, mix with an undesirable substance (e.g., dirt) and seal before placing in household trash.
Child-protection storage requirements Keep this medication out of the sight and reach of children and pets, and always lock safety caps.

Storage/Disposal Classifications (High-Level)

Classification Item Official Regulatory Terminology/Description
Storage condition type Controlled Room Temperature, Protected from Light, Keep Tightly Closed
Regulatory basis FDA / NIH / Regulatory Monographs
Storage-context constraints Must be protected from light, moisture, excessive heat, and freezing

Resulting Storage & Disposal Structure

Official storage and disposal statements:

  • Acebutolol must be stored at Controlled Room Temperature (20 C to 25 C) and protected from light, moisture, and excessive heat.
  • The medicine must not be frozen and should be kept in a light-resistant, tightly closed container.
  • Unused or expired medication must be disposed of; regulatory guidelines favor using drug take-back programs as the primary method.
  • The product must be secured and stored out of the reach of children.

Connection to the overall storage/disposal profile: Regulatory documents define the storage profile of Acebutolol by explicitly stating a required temperature range and mandatory environmental protection from light, moisture, and freezing. The product must be handled by keeping its container tightly closed, and disposal is officially mandated via authorized take-back programs or, alternatively, safely through household trash for product that is outdated or no longer needed. The profile also includes the mandatory instruction to secure the product away from children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acebutolol found in:

A-Z Index: